Literature DB >> 26106051

Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean.

Saori Takahashi1, Taku Yoshiya, Kumiko Yoshizawa-Kumagaye, Toshihiro Sugiyama.   

Abstract

Angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase which is highly homologous to angiotensin-converting enzyme (ACE). ACE2 produces vasodilator peptides angiotensin 1-7 from angiotensin II. In the present study, we synthesized various internally quenched fluorogenic (IQF) substrates (fluorophore-Xaa-Pro-quencher) based on the cleavage site of angiotensin II introducing N-terminal fluorophore N-methylanthranilic acid (Nma) and C-terminal quencher N(ε)-2,4- dinitrophenyl-lysine [Lys(Dnp)]. The synthesized mixed substrates "Nma-Xaa-Pro-Lys(Dnp)" were hydrolyzed by recombinant human (rh) ACE2. The amount of each product was determined by liquid chromatography mass spectrometry (LC-MS) with fluorescence detection and it was found that Nma-His-Pro-Lys(Dnp) is the most suitable substrate for rhACE2. The K(m), k(cat), and k(cat)/K(m) values of Nma-His-Pro-Lys(Dnp) on rhACE2 were determined to be 23.3 μM, 167 s(-1), and 7.17 μM(-1) s(-1), respectively. Using the rhACE2 and the newly developed IQF substrate, we found rhACE2 inhibitory activity in soybean and isolated the active compound soybean ACE2 inhibitor (ACE2iSB). The physicochemical data on the isolated ACE2iSB were identical to those of nicotianamine. ACE2iSB strongly inhibited rhACE2 activity with an IC50 value of 84 nM. This is the first demonstration of an ACE2 inhibitor from foodstuffs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26106051     DOI: 10.2220/biomedres.36.219

Source DB:  PubMed          Journal:  Biomed Res        ISSN: 0388-6107            Impact factor:   1.203


  26 in total

Review 1.  Promising natural products against SARS-CoV-2: Structure, function, and clinical trials.

Authors:  Yan Zhao; Shanshan Deng; Yujiao Bai; Jinlin Guo; Guoyin Kai; Xinhe Huang; Xu Jia
Journal:  Phytother Res       Date:  2022-08-05       Impact factor: 6.388

Review 2.  Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.

Authors:  Kunal Nepali; Ram Sharma; Sachin Sharma; Amandeep Thakur; Jing-Ping Liou
Journal:  J Biomed Sci       Date:  2022-09-06       Impact factor: 12.771

Review 3.  Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.

Authors:  Mark Laws; Yasmin M Surani; Md Mahbub Hasan; Yiyuan Chen; Peiqin Jin; Taha Al-Adhami; Madiha Chowdhury; Aqeel Imran; Ioannis Psaltis; Shirin Jamshidi; Kazi S Nahar; Khondaker Miraz Rahman
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

Review 4.  Current Findings Regarding Natural Components With Potential Anti-2019-nCoV Activity.

Authors:  Jin Zhou; Jie Huang
Journal:  Front Cell Dev Biol       Date:  2020-07-03

5.  Potentials of plant-based substance to inhabit and probable cure for the COVID-19.

Authors:  Israt Jahan; Ahmet Onay
Journal:  Turk J Biol       Date:  2020-06-21

Review 6.  Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19).

Authors:  Ehsaneh Khodadadi; Parham Maroufi; Ehsan Khodadadi; Isabella Esposito; Khudaverdi Ganbarov; Silvano Espsoito; Mehdi Yousefi; Elham Zeinalzadeh; Hossein Samadi Kafil
Journal:  Microb Pathog       Date:  2020-05-05       Impact factor: 3.738

7.  Potential interventions for novel coronavirus in China: A systematic review.

Authors:  Lei Zhang; Yunhui Liu
Journal:  J Med Virol       Date:  2020-03-03       Impact factor: 2.327

Review 8.  Recent advances in developing small-molecule inhibitors against SARS-CoV-2.

Authors:  Rong Xiang; Zhengsen Yu; Yang Wang; Lili Wang; Shanshan Huo; Yanbai Li; Ruiying Liang; Qinghong Hao; Tianlei Ying; Yaning Gao; Fei Yu; Shibo Jiang
Journal:  Acta Pharm Sin B       Date:  2021-07-02       Impact factor: 14.903

Review 9.  An overview on COVID-19: reality and expectation.

Authors:  Manal A Hamed
Journal:  Bull Natl Res Cent       Date:  2020-06-01

Review 10.  Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective.

Authors:  Yang Yang; Md Sahidul Islam; Jin Wang; Yuan Li; Xin Chen
Journal:  Int J Biol Sci       Date:  2020-03-15       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.